TARDBP and amyotrophic lateral sclerosis: For example, a study leveraged 3D spinal cord organoids derived from ALS patient iPSCs and electrophysiological tools to model disease-specific phenotypes and assess the efficacy of potential therapeutic compounds, identifying already-approved drugs with targets that modulate TDP-43 aggregates (Burkhardt et al., 2013).